ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Corporate Information, IR, News, Other Corporate Information, Swedish
November 18, 2024
19 Mar 2024

Acarix erhåller avsiktsförklaringar avseende nyttjande av teckningsoptioner av serie TO 2

Acarix AB (”Acarix” eller ”Bolaget”) har mottagit muntliga avsiktsförklaringar avseende nyttjande av Teckn...
Continue reading
author-avatar acarix
Corporate Information, English, IR, News, Other Corporate Information
November 18, 2024
19 Mar 2024

Acarix receives declarations of intent to exercise warrants of series TO 2

Acarix AB ("Acarix" or the "Company") has received oral declarations of intent to exercise Warrants of series TO 2 (the "Warrants") fro...
Continue reading
author-avatar acarix
Press
August 6, 2024
19 Mar 2024

Acarix erhåller avsiktsförklaringar avseende nyttjande av teckningsoptioner av serie TO 2

Acarix AB (”Acarix” eller ”Bolaget”) har mottagit muntliga avsiktsförklaringar avseende nyttjande av Teckningsoptionerna av serie TO 2 ...
Continue reading
author-avatar acarix
Press
August 6, 2024
19 Mar 2024

Acarix receives declarations of intent to exercise warrants of series TO 2

Acarix AB ("Acarix" or the "Company") has received oral declarations of intent to exercise Warrants of series TO 2 ...
Continue reading
author-avatar acarix
Press
August 6, 2024
15 Mar 2024

CEO purchases shares in Acarix

New York, New York, March 15, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Aamir Mahmood, rec...
Continue reading
author-avatar acarix
Press
August 6, 2024
15 Mar 2024

VD köper aktier i Acarix

New York, New York, 15 mars 2024 – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, meddelar att Aamir Mahmood, nyli...
Continue reading
author-avatar acarix
Corporate Information, IR, News, Other Corporate Information, Swedish
November 18, 2024
15 Mar 2024

VD köper aktier i Acarix

New York, New York, 15 mars 2024 – Acarix, ledande inom akustisk- och algoritmbaserad hjärtdiagnostik, meddelar att Aamir Ma...
Continue reading
author-avatar acarix
Corporate Information, English, IR, News, Other Corporate Information
November 18, 2024
15 Mar 2024

CEO purchases shares in Acarix

New York, New York, March 15, 2024 – Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Aamir Mahmoo...
Continue reading
author-avatar acarix
Corporate Information, English, IR, Listing Regulation, News, Other Corporate Information, Regulatory
November 18, 2024
06 Mar 2024

The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today

The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acarix" or the "Com...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 Mar 2024

Idag inleds utnyttjandeperioden för Acarix teckningsoptioner av serie 2024:U1 (TO2)

Utnyttjandeperioden för de teckningsoptioner av serie 2024:U1 (TO2) (”Teckningsoptioner”) som emitterades i samband med Acarix AB:s (”A...
Continue reading
author-avatar acarix
Corporate Information, IR, Listing Regulation, News, Other Corporate Information, Regulatory, Swedish
November 18, 2024
06 Mar 2024

Idag inleds utnyttjandeperioden för Acarix teckningsoptioner av serie 2024:U1 (TO2)

Utnyttjandeperioden för de teckningsoptioner av serie 2024:U1 (TO2) (”Teckningsoptioner”) som emitterades i samband me...
Continue reading
author-avatar acarix
Press
August 6, 2024
06 Mar 2024

The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today

The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acar...
Continue reading
  • «
  • ‹
  • 11
  • 12
  • 13
  • 14
  • 15
  • ›
  • »

Acarix AB

Jungmansgatan 12
211 19 Malmö
SE
info@acarix.com

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V6

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.